Genako Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 444.94%
- Profit Growth 409.77%
- Ebitda 109.30%
- Net Worth 46.43%
- Total Assets 13.56%
About Genako Pharma
Genako Pharma Private Limited (GPPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 April 2019 (Five years and ten months 1 days old ). Its registered office is in Pune, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Lalasaheb Jadhav, Saroja Jadhav, Sushant Shinde, and Two other members serve as directors at the Company.
Company Details
-
Location
Pune, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74999PN2019PTC183437
-
Company No.
183437
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
10 Apr 2019
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Genako Pharma?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amol Jadhav
|
Director | 13-Jul-2021 | Current |
|
Lalasaheb Jadhav
|
Director | 10-Apr-2019 | Current |
|
Saroja Jadhav
|
Director | 10-Apr-2019 | Current |
|
Sushant Shinde
|
Director | 13-Jul-2021 | Current |
|
Santoshkumar Shinde
|
Director | 24-Jul-2021 | Current |
Financial Performance of Genako Pharma.
Genako Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 444.94% increase. The company also saw a substantial improvement in profitability, with a 409.77% increase in profit. The company's net worth Soared by an impressive increase of 46.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Genako Pharma?
Unlock access to Genako Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Dinkarrao B Mane Agro Industries Private LimitedLalasaheb Jadhav is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Genako Pharma?
Unlock and access historical data on people associated with Genako Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genako Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genako Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.